Testing a drug to reduce hidden HIV early after treatment start
Treatments studied
Part of Infections clinical trials.
This trial tests whether adding venetoclax, a drug that helps infected cells die, at the start of HIV treatment can lower the amount of hidden virus that stays in the body. It may help reduce the HIV reservoir.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV and have never taken HIV medication before.
- You are between 18 and 70 years old.
- Your CD4 count is above 300 at screening.
- You agree to use condoms during sex until the virus is fully suppressed.
- You are not pregnant, breastfeeding, or planning to get pregnant or father a child during the study.
- You have not taken certain medications that could interact with the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of two lab-made antibodies plus an immunotherapy drug can help control HIV without daily antiretroviral pills. If successful, it might allow a safe break from your current HIV medications while keeping the virus under control.
This Phase 1/2 study tests whether venetoclax can help reduce the “HIV reservoir,” which is a hidden group of HIV-infected cells, while you stay on your usual HIV treatment. It also looks at whether the drug helps these infected cells die off in a controlled, safe way.
This study tests whether adding a new anti-HIV drug called lenacapavir to your regular HIV treatment can shrink the hidden reservoir of virus in your body. This could be a step toward a cure.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This study tests a new combination of two drugs to see if they can reduce the 'hidden' HIV that stays in your body even when you're on regular HIV treatment. The goal is to work toward a cure, not just control.
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
Hear when a new HIV-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.